Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
Journal Articles
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
Within 1 year, 15% of Canadian patients with severe asthma discontinue benralizumab. The reasons for discontinuation are not yet characterised. https://bit.ly/3kaRDlp.